Aclarion, Inc. (NASDAQ:ACON) Stock Short Interest Report for September

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totaling 48,934 shares, a drop of 35.6% from the September 15th total of 76,007 shares. Based on an average trading volume of 62,470 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.7% of the company’s stock are short sold.

Aclarion Trading Down 5.3%

ACON stock traded down $0.10 during midday trading on Friday, hitting $1.85. The company’s stock had a trading volume of 11,303 shares, compared to its average volume of 44,968. The firm’s 50-day moving average is $2.44 and its 200-day moving average is $2.83. Aclarion has a 12 month low of $1.85 and a 12 month high of $9.36. The company has a market cap of $5.33 million, a PE ratio of -0.25 and a beta of 1.20.

Aclarion (NASDAQ:ACON) last posted its earnings results on Thursday, August 6th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). Aclarion had a negative return on equity of 59.34% and a negative net margin of 10,948.81%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. Analysts expect that Aclarion will post -4.51 earnings per share for the current year.

Insider Buying and Selling at Aclarion

In related news, Director Ryan Bond purchased 21,122 shares of the stock in a transaction dated Thursday, August 13th. The stock was purchased at an average price of $2.37 per share, with a total value of $50,059.14. Following the transaction, the director directly owned 76,122 shares in the company, valued at $180,409.14. This trade represents a 38.40% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 51,863 shares of company stock worth $125,670 in the last ninety days. 0.01% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on ACON shares. Weiss Ratings raised shares of Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Aclarion from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.50.

About Aclarion

Aclarion, Inc (NASDAQ: ACON) is a healthcare technology company focused on improving the diagnosis and treatment planning of chronic low back pain. The company develops software designed to help physicians identify the spinal discs that may be contributing to a patient’s pain.

Its primary product, Nociscan, is a cloud-based platform that analyzes magnetic resonance spectroscopy data along with other imaging information. The system generates quantitative assessments, including Nociscores, intended to provide additional insight into disc health and support physicians in evaluating potential treatment options.

Aclarion’s technology is designed for use by spine specialists, radiologists, imaging centers and other healthcare providers.